Cambridge Cognition Holdings (LSE:COG), the digital brain health assessment specialist, has issued a run of announcements in recent weeks. On 6 October 2026 it said it had joined an NHS study led by Imperial College. In September it announced a Partnership with C2N and The Alzheimer's Trust and disclosed share purchases by directors. Those updates came shortly after interim results on 16 September, which showed higher Revenue and a narrower loss.
What the Company Does
Cambridge Cognition describes itself as a neuroscience technology company. It provides digital cognitive assessments under the CANTAB and Winterlight brands. Most of its income comes from pharmaceutical and biotechnology companies that use its tools to measure cognition in clinical studies. The interim results said clinical studies accounted for 89% of revenue. The group is also running pilot programmes in healthcare and consumer wellness. Earlier in 2026 it announced a brain health study with wearable technology company Oura.
Interim Results
In the six months to 30 June 2026, revenue rose 16% to about £5.04 million from £4.32 million a year earlier. That included around £0.1 million from the new healthcare and consumer pilots. Gross Margin improved to 75% from 72%. The adjusted EBITDA loss narrowed to about £0.30 million from £0.42 million, and the loss for the period fell to about £0.74 million. New sales orders were 13% lower at about £6.0 million. That figure excluded a £1.0 million contract signed three working days after the period ended. The order book stood at £16.1 million, slightly below the £16.4 million of a year earlier.
Chief executive Rob Baker said early signs from the new programmes were encouraging. He added that they were running "on time and on budget".
Funding and Balance Sheet
Cash at 30 June was about £0.58 million, but the company has since strengthened its position. In June it launched a share fundraising at 35p per share, made up of a placing, a subscription and a retail offer. The interim statement said gross proceeds were about £2.6 million. The money is earmarked for CE Mark and FDA 510(k) regulatory work, paediatric normative data sets and Winterlight automated speech recognition, with the rest going to working capital. Borrowings of about £0.22 million were repaid in full in July, leaving the group debt-free. The directors still flagged a material uncertainty over going concern, linked to turning future orders into cash. The company does not pay a dividend.
Sector and index Context
Cambridge Cognition is a small constituent of the FTSE AIM All Share Index. It is exposed to spending on clinical trials, particularly in neuroscience and Alzheimer's disease. As a specialist provider of digital cognitive measures for those trials, it depends on customers' development programmes, and trial timing can shift revenue between reporting periods.
Key Risks
The company noted that £0.7 million of contracted revenue had been pushed back to 2027, which shows how exposed it is to delays in customers' trials. Order intake fell in the first half. The Going Concern disclosure and modest cash balance mean execution against the order book remains important. The newer healthcare and consumer ventures are at an early stage.
What to Watch Next
Management expects full-year 2026 revenue of not less than £10.0 million, based on contracted orders. Investors will look for progress on the regulatory approvals funded by the June raise. They will also follow developments from the Imperial College NHS study and the C2N partnership, along with order intake in the second half.



_11_18_2026_06_43_20_247880.jpg)


Please wait processing your request...